BRAF and melanoma: The patients with a BRAF-mutant melanoma had a shorter median OS and PFS compared to patients with BRAF wild-type disease; median OS was 71 weeks vs. 130 weeks (HR for death for patients with a BRAF mutation was 1.96, 95% CI 1.02–3.77 p = 0.004, Table 5) and median PS was 35 weeks vs. 58 weeks (HR for progression 2.68, 95% CI 1.26–5.72 p = 0.011) (Figure 1c,d).